Now available in Spain — MedX helps detect skin cancer early.
By far the most common form of cancer is skin cancer. An estimated 4.3 million cases of basal cell carcinoma (BCC) are diagnosed in the U.S. each year. Squamous cell carcinoma (SCC) is the second most common form of skin cancer with more than 1 million cases of SCC diagnosed in the U.S. each year, resulting in more than 15,000 deaths. The most deadly of the skin cancers are melanoma. It is estimated that 7,230 deaths from melanoma in the US will occur this year. The annual cost of treating skin cancers in the U.S. is estimated at $8.1 billion.
MedX Health Corp. (TSXV: MDX) is a medical device company that has ownership of a technology that can scan suspicious moles and lesions. With their related software creating real-time images, SIAscopy™ can view up to 2 mm pain-free beneath suspicious moles and lesions that can allow physicians and dermatologists to make an evaluation within seconds. The Company’s suite of products are approved by Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, and Turkey.
MedX Health’s SIAscope device that can help detect skin cancers early
MedX Health is expanding globally
In Brazil, where skin cancer is prevalent MedX Health has already signed an exclusive distribution agreement to launch MedX Health’s early detection skin cancer product, DermSecure™.
Get our daily investorintel update
In Spain, MedX Health has now partnered (announced June 17, 2019) with a specialist healthcare and well-being service provider SANITAS to conduct a skin cancer screening initiative. According to studies, Spain has experienced a 50% increase in skin cancer rates in the last 10 years with half of all 65 year olds suffering from the cancer. The MedX-SANITAS partnership will take up to 3,000 patient scans using DermSecure™, to assess the benefits of such an initiative to SANITAS, its clients, and the Spanish healthcare system.
SANITAS forms part of Bupa, a leading international healthcare company, which serves over 15.7 million insurance policy holders and 15 million patients.
Speaking on behalf of SANITAS Dr. Miguel Marine Blanco commented: “With the increase in skin cancer rates in Spain we felt being able to offer our members skin cancer screening with the best screening technology available would be well received by our members.”
DermSecure™ telemedicine platform allows Doctors to view scans remotely
If recognized and treated early, melanoma is almost always curable, but if not it can spread to other parts of the body. In 2019 it is estimated in the US there will be close to 70,000 cases of invasive skin cancer that will penetrate into the second layer of the skin, the dermis. Melanoma is not the most common of the skin cancers, it is, however, the deadliest and it doesn’t have to be.
The world’s population is aging and it needs to be made aware that advances in medical innovation are out there helping them lead a healthier and longer life. MedX Health’s skin scanning technology SIAscopy™ offers not a cure, but a preventative technology helping early detection of one on mankind’s deadliest and most common cancers.
MedX is just starting to expand its global distribution and sales. If they can continue landing deals then larger revenues and profits will soon follow. Exciting times may well be ahead for MedX investors.
MedX Health Corp. is headquartered in Mississauga, Ontario; and has a market cap of C$ 21 million.
Matthew Bohlsen is a Senior Editor for InvestorIntel.com. With a Graduate Diploma in Applied Finance and Investment (similar to CFA), and a Graduate Diploma in ... <Read more about Matthew Bohlsen>